---
title: Review of 2022 PSOGI/RENAPE Consensus on HIPEC
date: '2024-09-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39285659/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240917194252&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: The 2022 PSOGI (Peritoneal Surface Oncology Group International) and
  RENAPE (French Network for Rare Peritoneal Malignancies) consensus on hyperthermic
  intraperitoneal chemotherapy (HIPEC) was a comprehensive effort aimed at standardizing
  treatment protocols for various peritoneal malignancies. This initiative is critical
  due to the wide range of technical variations in HIPEC procedures and the resulting
  need for standardization to ensure consistent and effective patient care and ...
disable_comments: true
---
The 2022 PSOGI (Peritoneal Surface Oncology Group International) and RENAPE (French Network for Rare Peritoneal Malignancies) consensus on hyperthermic intraperitoneal chemotherapy (HIPEC) was a comprehensive effort aimed at standardizing treatment protocols for various peritoneal malignancies. This initiative is critical due to the wide range of technical variations in HIPEC procedures and the resulting need for standardization to ensure consistent and effective patient care and ...